Mark Rubinstein to Immunotherapy
This is a "connection" page, showing publications Mark Rubinstein has written about Immunotherapy.
Connection Strength
1.425
-
IL-2 and Beyond in Cancer Immunotherapy. J Interferon Cytokine Res. 2018 02; 38(2):45-68.
Score: 0.529
-
IL-2Ra mediates temporal regulation of IL-2 signaling and enhances immunotherapy. Sci Transl Med. 2015 Oct 28; 7(311):311ra170.
Score: 0.452
-
Converting Tumoral PD-L1 into a 4-1BB Agonist for Safer and More Effective Cancer Immunotherapy. Cancer Discov. 2022 05 02; 12(5):1184-1186.
Score: 0.178
-
Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing. J Hematol Oncol. 2018 12 21; 11(1):142.
Score: 0.141
-
Review: novel nonviral delivery approaches for interleukin-12 protein and gene systems: curbing toxicity and enhancing adjuvant activity. J Interferon Cytokine Res. 2006 Sep; 26(9):593-608.
Score: 0.060
-
Fueling Cancer Immunotherapy With Common Gamma Chain Cytokines. Front Immunol. 2019; 10:263.
Score: 0.036
-
Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic. Cancer Immunol Immunother. 2016 Mar; 65(3):247-59.
Score: 0.029